SignalPath, LLC

SignalPath, LLC is a technology company dedicated to enhancing clinical trial management through its advanced platform, designed to streamline research processes and improve operational efficiency for healthcare organizations and pharmaceutical companies. SignalPath, LLC, founded in 2014, is based in Raleigh, US, and specializes in clinical trial management solutions. The company was co-founded by Bradly Nicholls and Kevin Monroe, with Bradly Nicholls also serving as CEO. The latest funding round, Series B, raised USD 18.

18 mn, which is the total amount raised by the company. SignalPath has completed 5 deals, with the most recent deal occurring on August 17, 2021. SignalPath's primary offering is the Viewpoint Site CTMS, an advanced clinical trial management system that digitizes study protocols and streamlines the management of clinical trials. This platform caters to a diverse client base, including enterprise research sites and healthcare organizations, addressing challenges in healthcare data management and clinical research across the United States, Europe, and Asia.

SignalPath generates revenue through a subscription-based model for the Viewpoint Site CTMS, allowing clients to manage clinical trials effectively. Revenue is also derived from bundled services that encompass data analytics and integration support, tailored to meet the specific needs of clients. Following its acquisition by Verily Life Sciences LLC in August 2021, SignalPath aims to enhance its clinical trial systems and evidence generation capabilities. The company plans to leverage this acquisition to introduce new products and expand its presence in global markets.

The funding from the acquisition will support these initiatives and strengthen SignalPath’s offerings in clinical research.